Mark Nedelman

Mark brings over 40 years of drug discovery and development experience to ANEWCRO, both as a client and veteran of the CRO industry. He has held leadership positions in academia (Massachusetts General Hospital), contributed to drug development in biopharma (Centocor and CeleCor Therapeutics), and led CRO industry efforts as GM at CRL and CEO of Ekam Imaging.

​

Previously, as CEO of Biomere, he developed and executed a strategy leading to its acquisition by Joinn Labs in 2019. Mark has co-authored over 50 peer-reviewed publications, three book chapters, and serves as a Trustee at Xenotherapeutics Foundation, a leading regenerative medicine non-profit.

April Hall

April Hall, Chief Business Officer, is a veteran of the CRO industry and a bioengineer by training. She has over 30 years of experience in pharmaceutical and medical device research. For the past 25 years, April focused on preclinical contract research business development. She served many leading contract labs including Charles River Laboratories, Transgenomics, Sinclair Research Center and Biomere/Joinn in this role. Her experience gives her a unique perspective supporting both sides of the development process, as a client herself developing devices and biologics as well as working with hundreds of clients to manage their preclinical programs globally. April’s diligence assures that our clients receive excellent responsiveness, quick study start times and services tailored to meet every need.

Steven Adams

Steven Adams DVM., MPVM, PhD, DACLAM is a scientist and veterinarian who has devoted his career to advancing health care and scientific research for animals and humans.   Dr. Adams received his BS, MPVM and DVM from the University of California and PhD in immunology/pathology from the College of Medicine at the University of Florida while also completing residency training in laboratory animal medicine.  Over his diverse career, he held a wide range of research and development, business, strategy and operational roles in biopharma before a career at Pfizer that spanned more than 24 years.  His last role at Pfizer was Vice President of Oncology Portfolio and Scientific Operations. 

Claudy Mullon, DSc

Dr. Mullon has 40 years of clinical and research experience in Pharmaceuticals, Medical Devices, and Biologics including organ and cell transplantation, liver disease, diabetes, dialysis, and artificial organs. 
He has held several managerial positions including VP of Medical Affairs and Clinical Research, Fresenius Medical Care North America; VP of R&D, W.R. Grace Co.; VP and co-founder of Circe Biomedical; Director of Clinical Research and Medical Affairs with Novartis Pharma (Transplantation, Immunology and Infectious Disease), and Director of Pharmacology, Surgery and Toxicology at Charles River Laboratories.
He received his doctorate from Washington University in St. Louis and completed his post-doctoral fellowship at MIT where he remained a research affiliate for 10 years
He has co-authored 65 articles published in peer-reviewed journals, 8 book chapters, over 200 abstracts presented at scientific congresses, and is an inventor on 21 US patents. He is a previous editorial board member of the Journal of Cell Transplantation, and the Journal of Regenerative Medicine (e-biomed). He is a current member of the American Society of Transplantation, an elected Fellow of the American Institute for Medical and Biological Engineering (AIMBE), and an elected Corporator of Emerson Hospital in Concord, MA. 

Hugh M. Davis, Ph.D.

Dr. Davis has over 35 years of scientific leadership and business experience in discovery research, early development, business development, strategic alliance, company operations and executive management in large pharma as the VP and Head of Biologics Clinical Pharmacology at Johnson & Johnson, in private biotech as the Chief Business and Development Officer at Biosion, Inc., in a CRO as Chief Business Officer at Frontage Laboratories (HKEX: 1521) and in a public US company as President and COO at Aclaris Therapeutics, Inc. (Nasdaq: ACRS). He is an established expert in the discovery and development of innovative biologics, from target ID/validation through creation of IND/CTA packages and execution of clinical programs across numerous therapeutic areas, especially oncology, immuno-oncology, immunology and cardiovascular medicine. Dr. Davis earned his Ph.D. and M.S. degrees in Biochemistry from Villanova University and a B.S. degree in Chemistry from Gannon University. He has published extensively, including authorship of over 75 scientific research articles and book chapters. Dr. Davis is currently serving on the Board of Directors of Aclaris Therapeutics, Inc. and Biosion, Inc. and on the Board of Directors and Scientific Advisory Board of ANEWCRO, LLC.